We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+3.44%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$938M
AUM Growth
-$133M
Cap. Flow
-$102M
Cap. Flow %
-10.88%
Top 10 Hldgs %
63.92%
Holding
49
New
11
Increased
10
Reduced
7
Closed
14

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$53.6M
2
AFMD
Affimed
AFMD
+$39M
3
NKTX icon
Nkarta
NKTX
+$27.2M
4
LEGN icon
Legend Biotech
LEGN
+$24.5M
5
SWTX
SpringWorks Therapeutics
SWTX
+$24.1M

Top Sells

Rank Stock Value
1
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$71.3M
2
GNMK
GenMark Diagnostics, Inc
GNMK
+$65.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$38.2M
4
MRSN
Mersana Therapeutics
MRSN
+$37.3M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.03%
2 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.3B
$93.4M 9.95%
558,162
+29,198
+6% +$4.87M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$88.4M 9.42%
1,201,399
+307,900
+34% +$24.1M
MGNX icon
3
MacroGenics
MGNX
$235M
$78.7M 8.39%
2,472,447
+172,618
+8% +$4.19M
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.75B
$70.2M 7.48%
2,709,709
-20,000
-0.7% -$506K
KROS icon
5
Keros Therapeutics
KROS
$199M
$54.8M 5.84%
890,209
+333,114
+60% +$21.1M
AFMD
6
DELISTED
Affimed
AFMD
$47.5M 5.07%
+600,897
New +$39M
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$44.6M 4.75%
993,912
+509,241
+105% +$23.7M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$43.7M 4.66%
255,203
-74,797
-23% -$14.8M
TPTX
9
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$42.6M 4.54%
+450,396
New +$53.6M
GMED icon
10
Globus Medical
GMED
$10.4B
$35.7M 3.8%
578,371
-330,582
-36% -$20.9M
ARVN icon
11
Arvinas
ARVN
$518M
$30.4M 3.24%
460,000
+35,000
+8% +$2.68M
VSTM icon
12
Verastem
VSTM
$532M
$27.7M 2.95%
933,451
+285,102
+44% +$7.99M
GMDA
13
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$26.8M 2.86%
3,318,207
+30,462
+0.9% +$280K
LEGN icon
14
Legend Biotech
LEGN
$4.3B
$26M 2.77%
+896,608
New +$24.5M
CASI
15
DELISTED
CASI Pharmaceuticals
CASI
$25.3M 2.7%
1,054,072
+296,429
+39% +$8.32M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.23B
$25M 2.67%
790,197
-920,606
-54% -$38.2M
ATRA icon
17
Atara Biotherapeutics
ATRA
$71.2M
$24M 2.56%
66,772
-74,538
-53% -$32.9M
STXS icon
18
Stereotaxis
STXS
$129M
$23.6M 2.51%
3,508,676
+373,500
+12% +$2.22M
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$21.2M 2.26%
+6,575,000
New +$21.9M
NKTX icon
20
Nkarta
NKTX
$162M
$18.8M 2%
+570,255
New +$27.2M
ACET icon
21
Adicet Bio
ACET
$72.8M
$15.9M 1.7%
+76,054
New +$17.5M
CFMS
22
DELISTED
Conformis, Inc. Common Stock
CFMS
$12.9M 1.37%
+520,000
New +$14M
CHFW.U
23
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$9.76M 1.04%
1,000,000
– –
SIOX
24
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.32M 0.89%
3,186,335
– –
CTIC
25
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.31M 0.78%
2,512,800
– –
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Consonance Capital Management held 49 positions worth $938M, down 12% from $1.07B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Consonance Capital Management withdrew a net $102M in Q1 2021, closing 14 positions and reducing 7 holdings. Its most notable exit was TCR2 Therapeutics Inc. Common Stock, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in Turning Point Therapeutics, Inc. Common Stock worth $42.6M.

  • Consonance Capital Management's largest Q1 2021 buy was Turning Point Therapeutics, Inc. Common Stock: 450,396 shares worth $42.6M.
  • Consonance Capital Management added most to SpringWorks Therapeutics in Q1 2021, an estimated $24.1M increase.
  • Consonance Capital Management's biggest Q1 2021 reduction was Iovance Biotherapeutics, cutting an estimated $38.2M.
  • Consonance Capital Management fully exited TCR2 Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $71.3M.
  • Consonance Capital Management's ten largest holdings make up 64% of its $938M portfolio in Q1 2021.
  • Consonance Capital Management opened 11 new positions and closed 14 in Q1 2021.
  • Consonance Capital Management's portfolio value fell 12% quarter-over-quarter to $938M.

Based on Consonance Capital Management's 13F filing for Q1 2021, filed 17 May 2021.